Europe Anti-Viral Therapies Market to Grow at a CAGR of 8.1% to reach US$ 21,122.66 Million from 2020 to 2027

Europe Anti-Viral Therapies Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type (Generic Drugs and Branded Drugs), Mechanism of Action (Nucleotide Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others), and Application (HIV, Hepatitis, Virus Influenza, Herpes, and Other Applications), and Country

  • Report Code : TIPRE00014170
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 120
Buy Now

The Europe anti-viral therapies market is expected to reach US$ 21,122.66 million by 2027 from US$ 11,401.67 million in 2019; it is estimated to grow at a CAGR of 8.1% from 2020 to 2027.

Increasing R&D expenditures of pharmaceutical companies and rising government support for research activities and clinical trials are the key factors driving the growth of the market in this region. However, high cost of drug development is a prime factor hindering the market growth in Europe.

Antiviral therapy is one of the most exciting branches of virology. These therapies are based on several strategies—direct-acting antivirals target viral proteins, enzymes, or nucleic acids; passive antibodies neutralize circulating viruses; and several other antivirals target cellular proteins or processes essential for viral replication.

The clinical trials industry has seen exceptional growth in the last 10 years. More than 600 commercial clinical trials are taking place in the UK National Health Service (NHS). The UK is one of the leading countries in the research and development activities in Europe. Also, the patients in the country are willingly participating in the clinical trials; ~870,250 people were a part of commercial and non-commercial trials. The government is also increasing funds for new research and clinical trials. Vaccine development to fight against COVID-19 is in high pace in the region due to the availability of large group of participants are focusing on clinical trials and forming collaborations to make certain rapid growth and sufficient production capacity. The UK government has launched a new clinical trial program—ACOORD—for the fast track development of new drugs to treat COVID-19. The recovery trial in the UK is currently the largest randomized clinical trial in the world. In Germany, >70% of the clinical trials are being supported by government organizations. The federal ministry of education and research of Germany has launched a pharmaceutical initiative to promote research and development activities. BioNTech and Pfizer have secured approval by German regulatory authority to conduct phase I/II clinical trial of COVID-19 vaccines. For instance, PharmaMar, Spain, has started their phase II clinical trials of a drug named Aplidin to treat COVID-19. Clinical trials of Ivermectin to treat COVID-19 already started. Thus, the biotechnology industry is at the forefront of the fight against COVID-19, contributing through the development of vaccines, therapeutic drugs, and diagnostics solutions. Further, ongoing research on the development of drugs for rare diseases is accelerating the growth of the Europe antiviral therapies market

Europe has witnessed exponential growth in the count of COVID-19 cases. Spain, Italy, Germany, France, and the UK are among the most affected European countries. Growing research activities to develop treatment against corona virus is likely to favor the growth of the market in this region. In June 2020, the scientists from the University of Oxford tested existing drugs as therapies against this novel virus. Further, the European Commission in July authorized the anti-viral drug Remdesivir for its use in the treatment of COVID-19 patients, making it the first approved drug in the European Union for the treatment.

Rest of Europe Anti-Viral Therapies Market, Revenue and Forecast to 2027 (US$ Million)

Rest of Europe Anti-Viral Therapies Market, Revenue and Forecast to 2027 (US$ Million)
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

EUROPE ANTI-VIRAL THERAPIES MARKET SEGMENTATION

By Type

  • Branded Drugs
  • Generic Drugs

By Mechanism of Action

  • Nucleotide Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Others

By Application

  • HIV
  • Hepatitis
  • Virus Influenza
  • Herpes
  • Others

By Country

  • Germany
  • UK
  • France
  • Italy
  • Spain

Company Profiles

  • AbbVie Inc.
  • GlaxoSmithKline plc
  • AstraZeneca
  • F. HOFFMANN-LA ROCHE LTD
  • Johnson and Johnson Services, Inc.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Type, Mechanism of Action, and Application, and Country

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

UK, Germany, France, Italy, Russia

The List of Companies - Europe Anti-Viral Therapies Market

  1. AbbVie Inc.
  2. GlaxoSmithKline plc
  3. AstraZeneca
  4. F. HOFFMANN-LA ROCHE LTD
  5. Johnson and Johnson Services, Inc.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Europe Anti-Viral Therapies Market